

Dotz enters into collaboration agreement for co-development, supply and licensing with a global biotech company

Highlights

- Dotz has entered into collaboration agreement for co-development, supply and licensing with Theracell Labs Ltd, a subsidiary of NASDAQ-listed biotech company Orgenesis Inc.
- Under the agreement, Theracell Labs has committed to a minimum purchase order of US\$5 million in the first year for the supply of Dotz-tagged disposable bioprocessing consumables subject to project and service deliverables still to be agreed by the parties
- Under the agreement, Dotz's end-to-end authentication technology will be used for, on and in-product tagging of biomedical consumables
- As part of the licensing arrangements in the agreement, Dotz and Theracell Labs are collaborating on a joint development of bio-imaging solutions to:
 - Tag patient-derived cells as an identification standard for quality assurance
 - Trace therapeutic cells in a patient's body to determine the treatment efficacy (subject to performance of the collaboration)
- If the collaboration agreement results in the successful development of a relevant commercialised product, Theracell Labs will be required to pay Dotz 5% of net revenue from the sale of the product in exchange for a global, perpetual, exclusive licence to manufacture, market, distribute and sell the technology

Dotz Nano Limited (ASX:DTZ, Dotz or the Company) an advanced technology company developing, manufacturing and commercialising marking, tracing and verification solutions, has entered into a co-development, supply and licensing collaboration agreement with Greece-based cell isolation technology company Theracell Labs Ltd (**Theracell Labs**) - a subsidiary of NASDAQ-listed global biotech Orgenesis Inc.

Theracell Labs is a developer of cell and gene therapy devices, treatments and processing systems.

Under the agreement, Dotz's end-to-end authentication technology will be used to mark disposable bioprocessing consumables, using on and in-product tagging techniques. Dotz's non-toxic taggants will be embedded directly in these products during manufacturing without impacting the appearance or properties of the products.

As part of the licensing arrangements in the agreement, Dotz and Theracell Labs will collaborate on the joint development of technology solutions to create an identification standard to tag patient-derived cells, facilitating real-time authentication of the patient's cells. Subject to the performance of the collaboration (including satisfaction of any agreed KPIs), the parties intend that the joint development will extend to include the ability to trace therapeutic cells in-vitro to determine treatment efficacy.



Under the agreement, Theracell Labs has committed to minimum purchase orders of US\$5 million in the first 12 months for the supply of Dotz-tagged disposable bioprocessing consumables, subject to agreed project and service deliverables. The agreed project deliverable is currently the supply of Dotz-tagged disposable bioprocessing consumables, however as the project progresses additional project deliverables are expected to be agreed between the parties. With Dotz's extensive expertise in tagging a variety of consumables, the Company does not envisage encountering any difficulties tagging these products.

If the collaboration agreement results in the successful development of a commercialised product for the gene and cell-based therapy sector and all necessary regulatory approvals are obtained in respect of the product (including in relation to the manufacturing, marketing, distribution, import, export and/or sale of the product):

- Theracell Labs will be granted an exclusive, perpetual, global licence to manufacture, market, distribute and sell the results of the collaboration for the gene and cell-based therapy sector; and
- Theracell Labs will be required to pay Dotz 5% of net revenue from the sale of the product.

Dotz notes that there is no certainty that the collaboration agreement for tagging petiend-derived cells will result in the successful development of a commercialised product for the gene and cell-based therapy sector, that the necessary regulatory approvals in respect of the product will be obtained (or that such approvals will be obtained in a timely manner) and/or that any sales or revenue will be achieved in respect of such product.

The agreement is open-ended and can be terminated by either party in the event of a material breach, within thirty (30) days after the receipt of written notice. Furthermore, the agreement is subject to KPIs required to be satisfied by Dotz, the nature of which are still to be agreed between the parties. Failure of such KPIs will entitle Theracell Labs to terminate the collaboration agreement with the prescribed period of written notice.

The collaboration agreement is not subject to a fixed term.

Commenting on the agreement, Dotz Chairman Bernie Brookes AM said, "This collaboration with a global biotech leader is testament to the innovation and versatility of our end-to-end authentication technology. Dotz's variety of advanced materials and in-depth and extensive knowledge in the development of novel taggants and fluorescent materials allow us to offer advanced traceability solutions for bio-imaging applications that increase treatment precision and efficiency. We look forward to a fruitful partnership with Tissue Genesis that will enable them to equip physicians with innovative solutions to achieve even better results for gene therapy treatments."

-ENDS-

This announcement has been authorised for release by the Board of Dotz Nano Limited.

For further information, please contact:

Investors:

Eric Kuret
Market Eye
E: eric.kuret@marketeye.com.au
P: +61 3 9591 8904

Media:

Tristan Everett
Market Eye
E: tristan.everett@marketeye.com.au
P: +61 403 789 096



About Dotz Nano Limited

Dotz Nano Limited (ASX: DTZ) is a technology leader in research, production and marketing of anti-counterfeiting, authentication and tracing solutions. Its unique products ValiDotz, BioDotz, Fluorensic and InSpec are exceptional solutions for numerous applications, such as: bio-imaging, liquids tagging, lubricants and DEF authentication, polymers tagging, anti-counterfeiting, brand & reputation protection and oil & gas industry.

To learn more about Dotz, please visit the website and corporate video via the following link www.dotz.tech

About Theracell Labs Ltd.

Established in 2019 as a Joint Venture (JV) between leading biotech companies Theracell Advanced Biotechnology and Orgenesis, Theracell Labs Ltd operates to advance the development of novel cell and gene therapy products using tailored processes to bring Advanced Therapy Medicinal Products (ATMPs) to patients at the therapeutic setting.

To learn more about Theracell Labs, please visit: <https://theracell.eu>